Novus Achieves Financial Growth and Pioneers Cannabis Integration in Prescription Drug Health Plans
Novus Acquisition and Development Corp. (NDEV) d/b/a as Novus Cannabis MedPlan has announced a period of exceptional financial performance and strategic innovation in the first half of 2025. The company’s recent achievements highlight its strong position as a leader in a new era of healthcare by integrating cannabis into health plans.
Financial Highlights
The company’s financial results for the first half of 2025 were robust. Gross revenue increased by 8.9%, while net revenue (EBITDA) saw a significant 17% jump in the second quarter compared to the previous year. This growth is a testament to Novus’s successful business model and market strategy. Furthermore, the company has maintained a strong financial foundation with disciplined management. Shareholder equity rose by 1.2% and cash and cash equivalents increased by 2.53%.
Shareholder Protection
Novus is also committed to fiscal transparency and shareholder protection. The company insiders have not sold any shares for three years and have no convertible notes, which prevents dilution. A “leak-out” policy for vendor stock sales further ensures market stability. CEO Frank Labrozzi’s publicly disclosed debt of $167,001 is a non-convertible instrument, reinforcing the company’s commitment to avoiding actions that could impact shareholder value.
Integration of Cannabis into Prescription Drug Plans
The true cornerstone of Novus’s strategy is its pioneering work in integrating cannabis into mainstream health plans. The company has secured discounts from nearly 25,000 generic and brand-name drugs from pharmaceutical manufacturers, enabling the creation of a complete, full prescription drug plan that includes cannabis. This innovative plan, which will be offered through its online Rx platform, is designed to make cannabis-based therapies more affordable and accessible. A key benefit is that premiums for this plan will be tax-deductible for Health Savings Accounts (HSAs).
Frank Labrozzi, Novus’s CEO, emphasized this vision: “We are at the forefront of a movement to legitimize and integrate cannabis into modern wellness plans. Our new prescription plan is a game-changer, and we are confident that this will not only benefit our members but also drive substantial growth for the company.”
Federal Legislation Scope
Favorable political winds are also supporting this progressive approach. President Trump’s recent positive comments about federal cannabis regulations are highly encouraging. The potential for a federal reclassification of cannabis validates Novus’s strategic direction and will accelerate the company’s ability to deliver its innovative solutions to a broader market. Novus is well-positioned to capitalize on this evolving landscape and lead the way in revolutionizing healthcare.
